Arvinas, Inc. - Common Stock (NQ:ARVN)

11.06 -0.16 (-1.43%)

Streaming Delayed Price Updated: 10:50 AM EDT, Apr 7, 2026 Add to My Watchlist

Price and Volume

Volume	113,365
Open	11.15
Bid (Size)	11.04 (100)
Ask (Size)	11.08 (200)
Prev. Close	11.22
Today's Range	10.80 - 11.33
52wk Range	5.900 - 14.51
Shares Outstanding	63,500,000
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Arvinas Announces Positive Phase 1 Data for ARV-102 Showing Greater Than 50% LRRK2 Degradation in the CSF of Patients with Parkinson’s Disease Treated for 28 Days

March 18, 2026

From Arvinas Inc.

Via GlobeNewswire

Arvinas to Present Phase 1 Data for ARV-102, a PROTAC LRRK2 Degrader, in Oral Session at the 2026 International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders

March 11, 2026

From Arvinas Inc.

Via GlobeNewswire

Performance

YTD	-3.6%	-3.6%
1 Month	-17.3%	-17.3%
3 Month	-1.0%	-1.0%
6 Month	+15.0%	+15.0%
1 Year	+73.6%	+73.6%

More News

Arvinas (ARVN) Q4 2025 Earnings Call Transcript ↗

February 24, 2026

Via The Motley Fool

Arvinas Inc (NASDAQ:ARVN) Stock Plummets After Q4 2025 Earnings and Revenue Miss Estimates ↗

February 24, 2026

Via Chartmill

Earnings Scheduled For November 5, 2025 ↗

November 05, 2025

Via Benzinga

Arvinas Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

February 24, 2026

From Arvinas Inc.

Via GlobeNewswire

Arvinas to Participate in Upcoming Investor Conferences

February 23, 2026

From Arvinas Inc.

Via GlobeNewswire

Arvinas to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026

February 17, 2026

From Arvinas Inc.

Via GlobeNewswire

ARVN Stock Drops On CEO Exit — Retail Is Bullish On New Chief’s Credentials, Dismisses Selloff ↗

February 12, 2026

Via Stocktwits

Arvinas Announces Appointment of Randy Teel, Ph.D., as President, Chief Executive Officer, and Director

February 12, 2026

From Arvinas Inc.

Via GlobeNewswire

Arvinas Presents Preclinical Data Supporting Mechanistic Synergies and Enhanced Antitumor Activity with the Combination of ARV-393 and Glofitamab at the 2025 American Society of Hematology Annual Meeting and Exposition

December 06, 2025

From Arvinas Inc.

Via GlobeNewswire

Arvinas to Present at Piper Sandler 37th Annual Healthcare Conference

November 26, 2025

From Arvinas Inc.

Via GlobeNewswire

Arvinas Announces Data Presentations from the Vepdegestrant (ARV-471) Clinical Development Program at the 2025 San Antonio Breast Cancer Symposium (SABCS)

November 24, 2025

From Arvinas Inc.

Via GlobeNewswire

Top movers in Tuesday's session ↗

November 18, 2025

Via Chartmill

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

November 18, 2025

Via Benzinga

Let's uncover which stocks are experiencing notable gaps during today's session. ↗

November 18, 2025

Via Chartmill

Amer Sports Posts Upbeat Q3 Earnings, Joins Diginex, James Hardie Industries And Other Big Stocks Moving Higher On Tuesday ↗

November 18, 2025

Via Benzinga

These stocks that are showing activity before the opening bell on Tuesday. ↗

November 18, 2025

Via Chartmill

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

November 18, 2025

Via Benzinga

Arvinas Inc (NASDAQ:ARVN) Tops Q3 2025 Earnings Estimates and Provides Pipeline Updates ↗

November 05, 2025

Via Chartmill

Arvinas Reports Third Quarter 2025 Financial Results and Provides Corporate Update

November 05, 2025

From Arvinas Inc.

Via GlobeNewswire

Arvinas to Present Preclinical Data for ARV-393 at the 2025 American Society of Hematology (ASH) Annual Meeting

November 03, 2025

From Arvinas Inc.

Via GlobeNewswire

Arvinas to Participate in Upcoming Investor Conferences

November 03, 2025

From Arvinas Inc.

Via GlobeNewswire

Arvinas to Report Third Quarter 2025 Financial Results on November 5, 2025

October 29, 2025

From Arvinas Inc.

Via GlobeNewswire

Arvinas Presents Preclinical Data for ARV-806 Demonstrating Robust and Differentiated Activity in Models of KRAS G12D-mutated Cancer at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

October 24, 2025

From Arvinas Inc.

Via GlobeNewswire

Frequently Asked Questions

Is Arvinas, Inc. - Common Stock publicly traded?

Yes, Arvinas, Inc. - Common Stock is publicly traded.

What exchange does Arvinas, Inc. - Common Stock trade on?

Arvinas, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Arvinas, Inc. - Common Stock?

The ticker symbol for Arvinas, Inc. - Common Stock is ARVN on the Nasdaq Stock Market

What is the current price of Arvinas, Inc. - Common Stock?

The current price of Arvinas, Inc. - Common Stock is 11.06

When was Arvinas, Inc. - Common Stock last traded?

The last trade of Arvinas, Inc. - Common Stock was at 04/07/26 10:50 AM ET

What is the market capitalization of Arvinas, Inc. - Common Stock?

The market capitalization of Arvinas, Inc. - Common Stock is 702.31M

How many shares of Arvinas, Inc. - Common Stock are outstanding?

Arvinas, Inc. - Common Stock has 702M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.